Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC
The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.